Tags

Type your tag names separated by a space and hit enter

Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy.
CMAJ 2010; 182(17):1857-62CMAJ

Abstract

BACKGROUND

The intake of soy isoflavones among women with breast cancer has become a public health concern, because these compounds have weak estrogenic effects. There is little clinical evidence about their safety for patients with breast cancer who are receiving adjuvant endocrine therapy.

METHODS

For patients who underwent surgery for breast cancer between August 2002 and July 2003 and who were receiving adjuvant endocrine therapy, we examined associations between dietary intake of soy isoflavones and recurrence of breast cancer and death. We measured dietary intake of soy isoflavones at baseline using a validated food frequency questionnaire. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) by means of multivariable Cox proportional hazards regression models. We further stratified the analyses by hormonal receptor status and endocrine therapy.

RESULTS

The median follow-up period for the 524 patients in this study was 5.1 years. Among premenopausal patients, the overall death rate (30.6%) was not related to intake of soy isoflavones (HR = 1.05, 95% CI 0.78-1.71 for the highest quartile [> 42.3 mg/day] v. the lowest quartile [< 15.2 mg/day], p for trend = 0.87). Relative to post-menopausal patients in the lowest quartile of soy isoflavone intake, the risk of recurrence for post-menopausal patients in the highest quartile was significantly lower (HR = 0.67, 95% CI 0.54-0.85, p for trend = 0.02). Inverse associations were observed in patients with estrogen and progesterone receptor positive disease and those receiving anastrozole therapy.

INTERPRETATION

High dietary intake of soy isoflavones was associated with lower risk of recurrence among post-menopausal patients with breast cancer positive for estrogen and progesterone receptor and those who were receiving anastrozole as endocrine therapy.

Authors+Show Affiliations

Department of Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20956506

Citation

Kang, Xinmei, et al. "Effect of Soy Isoflavones On Breast Cancer Recurrence and Death for Patients Receiving Adjuvant Endocrine Therapy." CMAJ : Canadian Medical Association Journal = Journal De l'Association Medicale Canadienne, vol. 182, no. 17, 2010, pp. 1857-62.
Kang X, Zhang Q, Wang S, et al. Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy. CMAJ. 2010;182(17):1857-62.
Kang, X., Zhang, Q., Wang, S., Huang, X., & Jin, S. (2010). Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy. CMAJ : Canadian Medical Association Journal = Journal De l'Association Medicale Canadienne, 182(17), pp. 1857-62. doi:10.1503/cmaj.091298.
Kang X, et al. Effect of Soy Isoflavones On Breast Cancer Recurrence and Death for Patients Receiving Adjuvant Endocrine Therapy. CMAJ. 2010 Nov 23;182(17):1857-62. PubMed PMID: 20956506.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy. AU - Kang,Xinmei, AU - Zhang,Qingyuan, AU - Wang,Shuhuai, AU - Huang,Xu, AU - Jin,Shi, Y1 - 2010/10/18/ PY - 2010/10/20/entrez PY - 2010/10/20/pubmed PY - 2010/12/18/medline SP - 1857 EP - 62 JF - CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne JO - CMAJ VL - 182 IS - 17 N2 - BACKGROUND: The intake of soy isoflavones among women with breast cancer has become a public health concern, because these compounds have weak estrogenic effects. There is little clinical evidence about their safety for patients with breast cancer who are receiving adjuvant endocrine therapy. METHODS: For patients who underwent surgery for breast cancer between August 2002 and July 2003 and who were receiving adjuvant endocrine therapy, we examined associations between dietary intake of soy isoflavones and recurrence of breast cancer and death. We measured dietary intake of soy isoflavones at baseline using a validated food frequency questionnaire. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) by means of multivariable Cox proportional hazards regression models. We further stratified the analyses by hormonal receptor status and endocrine therapy. RESULTS: The median follow-up period for the 524 patients in this study was 5.1 years. Among premenopausal patients, the overall death rate (30.6%) was not related to intake of soy isoflavones (HR = 1.05, 95% CI 0.78-1.71 for the highest quartile [> 42.3 mg/day] v. the lowest quartile [< 15.2 mg/day], p for trend = 0.87). Relative to post-menopausal patients in the lowest quartile of soy isoflavone intake, the risk of recurrence for post-menopausal patients in the highest quartile was significantly lower (HR = 0.67, 95% CI 0.54-0.85, p for trend = 0.02). Inverse associations were observed in patients with estrogen and progesterone receptor positive disease and those receiving anastrozole therapy. INTERPRETATION: High dietary intake of soy isoflavones was associated with lower risk of recurrence among post-menopausal patients with breast cancer positive for estrogen and progesterone receptor and those who were receiving anastrozole as endocrine therapy. SN - 1488-2329 UR - https://www.unboundmedicine.com/medline/citation/20956506/Effect_of_soy_isoflavones_on_breast_cancer_recurrence_and_death_for_patients_receiving_adjuvant_endocrine_therapy_ L2 - http://www.cmaj.ca/cgi/pmidlookup?view=long&amp;pmid=20956506 DB - PRIME DP - Unbound Medicine ER -